Rheumatology Search
Rheumatology Rheumatology
fibromyalgia
FIBROMYALGIA

Fibromyalgia is a clinical syndrome wherein the patient experiences generalized pain and fatigue that cannot be explained by the presence of any other disorder.
It is often considered to be psychosomatic or psychogenic in nature.
It is found in approximately 2% of the population and the prevalence increases with age, most common in women 20-55 year of age

Fibromyalgia Drug Information

Drug Information

Indication: Neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisatio...

Indication: Peripheral & central neuropathic pain, generalised anxiety disorder (GAD) in adults. Adjunctive therapy in...

Indication: Adjunctive therapy in treatment of partial seizures w/ & w/o secondary generalization in adults & chil...

Indication: Signs & symptoms of advanced idiopathic Parkinson's disease as monotherapy or in combination w/ levodopa. ...

Indication: Signs & symptoms of advanced idiopathic Parkinson's disease as monotherapy or in combination w/ levodopa.

Indication: Moderate to severe pain.

Indication: Moderate to severe pain.

Indication: Severe acute & chronic pain. Painful diagnostic or therapeutic measures.

Indication: Moderate to severe acute & chronic pain & in painful diagnostic measure & surgery.

Indication: Major depressive disorder, generalized anxiety disorder. Management of diabetic peripheral neuropathic pain.

1  /  4
1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Product Highlight - ADACEL
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Spotlight on multidrug-resistant gram-negative infections: New developments for an old problem
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
B-cells remember COVID-19, protect against reinfection
Tristan Manalac, Yesterday
While antibody titres against SARS-CoV-2 wane with time, the immune system is capable of producing memory B-cells that can last for at least 6 months after infection, suggesting that the body will be able to protect itself in the case of re-exposure, according to a new study.
Standing good for heart health
Jairia Dela Cruz, 5 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.